Metabolites of SHetA2 as Anti-Cancer Agents
- Summary
- OSU researchers haveidentified and synthesized amajor metabolite (active molecule) of SHetA2 as well as a conjugate (compound) form of themetabolite. The conjugate can be used todetermine the specific proteins that promote cancer development, thus providingthe type of information that is necessary to construct new compounds that will improvethe anti-cancer activity of SHetA2.
- Technology Benefits
- Effectively induces cell death in cancer cells Shows no toxicity to normal cells in animal trials Human trials slated to begin in near future
- Technology Application
- Cancer treatment
- Detailed Technology Description
- None
- *Abstract
-
None
- *Background
- SHetA2 has previously been identified by OSU researchers asa strong anti-cancer agent that induces apoptosis (cell death) in 8different types of kidney cancer cells and is being developed fortreatment of Polycystic Kidney Disease (PKD). SHetA2 is in the final stages of preclinical testing andsince no toxicity to normal cells has been observed by National CancerInstitute (NCI) in trials with mice, rats, and dogs, clinical trials will beginon human patients in the near future.
- *Stage of Development
- Prototype is available.
- Country/Region
- USA
For more information, please click Here
